L'intérêt à découvert pour Merit Medical Systems donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Merit Medical Systems. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Merit Medical Systems (NASDAQ:MMSI) Stock, Rapport sur les intérêts à découvert

Merit Medical Systems

Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems Inc

Across the recent three months, 8 analysts have shared their insights on Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $114.62, a high estimate of $127.00, and a low estimate of $109.00. This current average reflects an increase of 2.91% from the previous average price target of $111.38. 
<img src="https://www.benzinga.com/files/images/story/2024/1735668014_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Merit Medical Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$114.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$109.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$114.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$109.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$114.00</td>
<td>$114.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Merit Medical Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Merit Medical Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Merit Medical Systems's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Discovering Merit Medical Systems: A Closer Look</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.
<h3>Financial Milestones: Merit Medical Systems's Journey</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Merit Medical Systems's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 7.81%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Merit Medical Systems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.37%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Merit Medical Systems's ROE stands out, surpassing industry averages. With an impressive ROE of 2.18%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.2%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.62.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

MMSI

What 8 Analyst Ratings Have To Say About Merit Medical Systems

Raymond James analyst Jayson Bedford maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and raises the price target from $105 to $110.

News

Price Target

Raymond James Maintains Outperform on Merit Medical Systems, Raises Price Target to $110

Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and maintains $114 price target.

Barrington Research Maintains Outperform on Merit Medical Systems, Maintains $114 Price Target

Merit Medical Secures FDA Approval For WRAPSODY Cell-Impermeable Endoprosthesis, Extending Life-Saving Treatment For Dialysis Patients With U.S. Commercialization Set For 2025

In the current market session, Merit Medical Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) share price is at $97.14, after a 0.01% increase. Moreover, over the past month, the stock decreased by 7.52%, but in the past year, went up by 28.50%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1734632112_0.png" alt="Past Year Chart" />

<h3>Comparing Merit Medical Systems P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 44.09 in the Health Care Equipment &amp; Supplies industry, Merit Medical Systems Inc. has a higher P/E ratio of 47.38. Shareholders might be inclined to think that Merit Medical Systems Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734632112_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: Merit Medical Systems

Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025.
The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance.
Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President.

Management

Merit Medical Announces Resignation Of President, Joseph Wright, Effective January 3, 2025; Board Of Directors Has Re-Appointed Fred P. Lampropoulos As Merit's President

In the latest quarter, 11 analysts provided ratings for Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $111.55, a high estimate of $127.00, and a low estimate of $103.00. Witnessing a positive shift, the current average has risen by 5.88% from the previous average price target of $105.36.
<img src="https://www.benzinga.com/files/images/story/2024/1733925642_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Merit Medical Systems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$109.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$114.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$109.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$114.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$114.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$109.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$103.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$103.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Merit Medical Systems. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Merit Medical Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Merit Medical Systems's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Discovering Merit Medical Systems: A Closer Look</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.
<h3>Key Indicators: Merit Medical Systems's Financial Health</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Merit Medical Systems displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.81%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Merit Medical Systems's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.37% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Merit Medical Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.18%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.2%, the company showcases effective utilization of assets.
Debt Management: Merit Medical Systems's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.62.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Merit Medical Systems Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

Wells Fargo analyst Larry Biegelsen upgrades Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) from Equal-Weight to Overweight and raises the price target from $103 to $120.

Upgrades

Wells Fargo Upgrades Merit Medical Systems to Overweight, Raises Price Target to $120

Canaccord Genuity analyst Jon Young maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and raises the price target from $125 to $127.

Canaccord Genuity Maintains Buy on Merit Medical Systems, Raises Price Target to $127

Merit Medical Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NYSE">MMSI</a>) short percent of float has risen 16.01% since its last report. The company recently reported that it has 2.69 million shares sold short, which is 6.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.26 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Merit Medical Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731952822_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Merit Medical Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Merit Medical Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Merit Medical Systems's peer group average for short interest as a percentage of float is 6.68%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Merit Medical Systems?

A substantial insider activity was disclosed on November 7, as Peterson, Chief Operating Officer at Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), reported the exercise of a large sell of company stock options.
What Happened: Peterson, Chief Operating Officer at Merit Medical Systems, exercised stock options for 5,000 shares of MMSI stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000856982/000141588924026373//Archives/edgar/data/856982/000141588924026373/0001415889-24-026373-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The exercise price of the options was $54.4 per share.
The Friday morning update indicates Merit Medical Systems shares up by 0.49%, currently priced at $102.47. At this value, Peterson's 5,000 shares are worth $240,350.
<h3>Delving into Merit Medical Systems's Background</h3>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.
<h3>Breaking Down Merit Medical Systems's Financial Performance</h3>
Revenue Growth: Merit Medical Systems displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.81%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 46.36%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Merit Medical Systems's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.49.
</li>
</ul>
Debt Management: Merit Medical Systems's debt-to-equity ratio surpasses industry norms, standing at 0.62. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: Merit Medical Systems's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 49.74.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 4.52 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Merit Medical Systems's EV/EBITDA ratio stands at 21.82, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000856982">Check Out The Full List Of Merit Medical Systems's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Strategic Sale: Neil Peterson Decides To Exercise Options Worth $240K At Merit Medical Systems

Needham analyst Mike Matson reiterates Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and maintains $109 price target.

Reiteration

Needham Reiterates Buy on Merit Medical Systems, Maintains $109 Price Target

Baird analyst David Rescott maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and raises the price target from $107 to $109.

Baird Maintains Outperform on Merit Medical Systems, Raises Price Target to $109

Guidance

Merit Medical Updates FY24 Adj. EPS From $3.25-$3.34 To $3.33-$3.38 Vs $3.30 Est.; Net Sales $1.339B-$1.351B To $1.344B-$1.352B Vs $1.344B Est.

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.80 by 7.5 percent. The company reported quarterly sales of $339.800 million which beat the analyst consensus estimate of $334.621 million by 1.55 percent. This is a 7.79 percent increase over sales of $315.230 million the same period last year.

Earnings

Earnings Beats

Merit Medical Systems Q3 2024 Adj. EPS $0.86 Beats $0.80 Estimate, Sales $339.800M Beat $334.621M Estimate

11 analysts have expressed a variety of opinions on Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $104.45, a high estimate of $114.00, and a low estimate of $92.00. Marking an increase of 7.18%, the current average surpasses the previous average price target of $97.45. 
<img src="https://www.benzinga.com/files/images/story/2024/1729281711_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Merit Medical Systems by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$114.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$114.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$109.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$103.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$103.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Merit Medical Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Merit Medical Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Merit Medical Systems's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Unveiling the Story Behind Merit Medical Systems</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.
<h3>Merit Medical Systems's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Merit Medical Systems displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 5.61%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Merit Medical Systems's net margin is impressive, surpassing industry averages. With a net margin of 10.57%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Merit Medical Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.83%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Merit Medical Systems's ROA excels beyond industry benchmarks, reaching 1.52%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.68.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Merit Medical Systems Stands With Analysts

Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and raises the price target from $100 to $114.

Barrington Research Maintains Outperform on Merit Medical Systems, Raises Price Target to $114

Needham analyst Mike Matson maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and raises the price target from $105 to $109.

Needham Maintains Buy on Merit Medical Systems, Raises Price Target to $109

Craig Bijou, an analyst from Bank of America Securities, reiterated the Hold rating on Merit Medical Systems (MMSI – Research Report). The associat...

Hold Rating Issued for Merit Medical Systems Amid Leadership Changes and Uncertain Succession Plan

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Merit Medical Systems (MMSI – Research Report) yesterday and set a price target of $...

Positive Outlook for Merit Medical Systems Amid Leadership Transition and Imminent Wrapsody Approval

Merit Medical Systems ( ($MMSI) ) has shared an announcement. Merit Medical Systems announced the resignation of its President, Joseph C. Wright, e...

Merit Medical Systems Announces Leadership Change Amid Investigation

Merit Medical (MMSI) Systems announced that the WRAPSODY Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug ...

Merit Medical announces FDA approval of WRAPSODY Cell-Impermeable Endoprosthesis

Merit Medical gets FDA approval for WRAPSODY dialysis device

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSX – Research Report), Vivani Me...

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Vivani Medical (VANI) and Merit Medical Systems (MMSI)

Analyst Michael Petusky from Barrington maintained a Buy rating on Merit Medical Systems (MMSI – Research Report) and keeping the price target at $...

Merit Medical Systems: Promising Growth with Wrapsody Device Approval and Market Expansion

Barrington analysts revealed the firm's best stocks ideas list for 2025: Asure Software (ASUR), Carriage Services (CSV), Cimpress (CMPR), Dolby (DL...

Barrington reveals best stocks ides for 2025

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Merit Medical Systems (MMSI – Research Report), with a price...

Comments

Merit Medical Systems

Intérêt court

Merit Medical Systems (NASDAQ:MMSI) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL